Loading…
Korean drugmaker best known for eye drops, developing an Eylea biosimilar and oral GLP-1 and long-acting injectable drugs.
Korean drugmaker best known for eye drops, developing an Eylea biosimilar and oral GLP-1 and long-acting injectable drugs.
Earns mainly from ophthalmic (eye) products, about half of sales, plus cardiovascular and antibiotic drugs, and exports eye drops to Europe and the US. Its next growth step is an Eylea biosimilar (a near-copy of a biologic drug) sold through partners, Fresenius Kabi in the US and Apotex in Canada, after an August 2026 patent settlement with Regeneron and Bayer.
Moat: narrow (process know-how, regulatory licence). EU-GMP-certified eye-drop manufacturing and partnered biosimilar sales; many Korean and global drugmakers compete.
Headquarters: Seoul, South Korea · Founded: 1943 · Employees: 436
Size Sam Chun Dang Pharm (000250.KS) is a South Korea Health Care company (Pharmaceuticals: Major) with a market value of $2.91B, the 101st largest of 495 South Korea companies the cockpit tracks. Shares closed at ₩170,100 on 6 Nov 2026.
Performance Over six months the shares fell 59.1%, against -2.8% for the median peer and -24.5% for the South Korea market (cap-weighted) — 2nd lowest of 21 in its peer set.
Growth Revenue grew 20.8% over the last twelve months (peer median +14.8%); the operating margin is 6.8% (peer median 15.6%).
Valuation It trades at 15.4× enterprise value to sales against a peer median of 6.7× (7th most expensive of 20).
Capital Return on invested capital runs 5.7 points below its cost of capital (8.6% WACC).
Next results Next results expected around 12 Nov 2026 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ₩260B | ₩232B | ₩211B | ₩193B | ₩177B |
| Revenue growth | — | +10% | +9% | +9% | — |
| Gross profit | ₩120B | ₩106B | ₩97.0B | ₩94.5B | ₩87.9B |
| EBITDA | ₩29.5B | ₩19.3B | ₩26.0B | ₩18.1B | ₩20.2B |
| Net income | ₩17.8B | ₩5.26B | -₩10.9B | -₩10.4B | ₩5.84B |
| Free cash flow | -₩30.6B | -₩36.4B | ₩4.75B | ₩16.7B | -₩3.25B |
| Capital expenditure | ₩85.7B | ₩59.6B | ₩41.3B | ₩22.0B | ₩46.5B |
| Total debt | ₩52.0B | ₩69.8B | ₩49.9B | ₩53.6B | ₩76.6B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| Sam Chun Dang Pharm 000250.KS | $2.91B | -59% | +21% | 7% | 15.4× | n/a |
| Santen Pharmaceutical 4536.T | $3.86B | +17% | -1% | 16% | 1.9× | -5.2% |
| Celltrion 068270.KS | $34.3B | +10% | +40% | 32% | 8.6× | 8.3% |
| Alvotech ALVO | $1.90B | +49% | -12% | 9% | 6.5× | n/a |
| Formycon FYB.DE | $280M | -26% | +18% | -26% | 3.4× | n/a |
| HanmiPharm 128940.KS | $4.36B | +2% | +14% | 16% | 3.5× | 5.0% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 000250.KS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -29.4% | +2.2% | 3rd lowest of 21 |
| 6-month return | -59.1% | -2.8% | 2nd lowest of 21 |
| Distance from 52-week high | -86.2% | -23.2% | 2nd lowest of 21 |
| Revenue growth (TTM) | +20.8% | +14.8% | 9th highest of 20 |
| Operating margin | 6.8% | 15.6% | 7th lowest of 20 |
| EV / Sales | 15.4× | 6.7× | 7th most expensive of 20 |
| ROIC minus cost of capital | -5.7 pp | +1.1 pp | 3rd lowest of 16 |
| Net debt / EBITDA | -1.7× | -1.3× | 4th least indebted of 7 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Sam Chun Dang Pharm 000250.KS | South Korea | $2.91B | -59% | +21% | 7% | 15.4× | n/a | n/a |
| Joincare Pharmaceutical Group Industry 600380.SS | China | $2.86B | -4% | -12% | 18% | 1.6× | -13.1% | +2.4% |
| Betta Pharmaceuticals 300558.SZ | China | $3.01B | -9% | +16% | 11% | 5.8× | 25.2% | +14.0% |
| IDEAYA Biosciences IDYA | United States | $3.02B | +10% | -83% | -1,267% | 60.5× | n/a | n/a |
| Vericel VCEL | United States | $2.80B | +63% | +23% | 6% | 8.9× | 50.7% | +17.3% |
| InSilico Medicine Cayman TopCo 3696.HK | Hong Kong | $2.80B | -43% | +153% | -7% | 16.6× | 42.1% | +22.9% |
| BioArctic BIOA-B.ST | Sweden | $2.78B | -3% | -46% | 22% | 25.3× | 25.7% | +100.1% |
| Kangmei Pharmaceutical 600518.SS | China | $2.77B | -22% | -6% | -7% | 3.5× | n/a | n/a |
| Hybio Pharmaceutical 300199.SZ | China | $3.08B | +16% | +70% | 31% | 14.7× | 40.1% | +6.1% |
| Almirall ALM.MC | Spain | $2.74B | -2% | +24% | 8% | 2.1× | 7.3% | +6.5% |
| Acrobiosystems 301080.SZ | China | $2.72B | +95% | +29% | 17% | 16.7× | 45.0% | +27.7% |
| Yili Chuanning Biotechnology 301301.SZ | China | $2.70B | -20% | -14% | 16% | 4.5× | 4.6% | +4.8% |
| Neuland Laboratories NEULANDLAB.NS | India | $2.68B | +14% | +50% | 26% | 10.9× | n/a | n/a |
| Chengdu Kanghong Pharmaceutical 002773.SZ | China | $3.18B | -7% | -11% | 24% | 3.6× | -2.2% | +7.0% |
| Tasly Pharmaceutical 600535.SS | China | $3.20B | -5% | -4% | 19% | 2.3× | -7.6% | -9.6% |
| Arcutis Biotherapeutics ARQT | United States | $3.21B | +21% | +76% | 7% | 6.7× | 48.9% | +367.3% |
| Viridian Therapeutics VRDN | United States | $3.23B | +72% | -63% | -1,781% | 99.3× | n/a | n/a |
| Regencell Bioscience RGC | United States | $2.61B | -82% | n/a | n/a | n/a | n/a | n/a |
| Acutaas Chemicals ACUTAAS.NS | India | $3.28B | +39% | +45% | 36% | 19.3× | n/a | n/a |
| HUTCHMED (China) 0013.HK | Hong Kong | $2.58B | +9% | -9% | -6% | 2.4× | 49.9% | +19.3% |
| China Medical System 0867.HK | Hong Kong | $3.30B | -16% | +15% | 20% | 2.1× | 2.9% | +2.7% |